Bone Therapeutics SA : Provides Update on Equity Placement 15 december 2017 16:45Regulated Information - Inside Information - 15 December 2017 - 4:45 pm CET NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Bone Therapeutics Provides Update on Equity PlacementGosselies, Belgium, 15 December 2017, 4:45 pm CET - Bone Therapeutics (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases (the " Company "), announces that it has cancelled its private placement to raise funds via an accelerated bookbuild offering (the " Offering ") despite strong investor interest. Pharmstandard International S.A., a fully owned subsidiary of Pharmstandard, JSC and the investment arm of a group of companies which includes Cellthera Pharm LLC had publicly expressed its intention to participate in the Offering. However, this intention was unexpectedly withdrawn at short notice. As the Company had previously announced the intention of Pharmstandard International S.A. to participate, the terms of the transaction as communicated by the Company are no longer valid. As a consequence, the Company has also decided to cease discussions with Cellthera Pharm LLC with regards to a potential collaboration.Bone Therapeutics is encouraged by the level of interest in the Offering with both existing shareholders and international and local new investors.The Company remains focused on meeting its financial needs in order to achieve its strategic goals.